Table 2.
Clinical characteristics of nondiabetic study subjects
| Variable | NDC-lean | NDC-ow | NDC-all | IgAGN |
|---|---|---|---|---|
| N (male/female) | 219 (96/123) | 126 (81/45)* | 345 (177/168) | 98 (61/37) |
| Age (years) | 33 ± 10 | 33 ± 9 | 33 ± 10 | 52 ± 13* |
| BMI (kg/m2) | 22.2 ± 1.7 | 28.2 ± 2.8* | 24.3 ± 3.6 | 26.5 ± 4.3* |
| Waist (cm) | ||||
| Male | 85 (80–88) | 97 (92–102)† | 89 (84–96) | 91 (87–100) |
| Female | 76 (72–81) | 90 (86–98)* | 79 (74–85) | 80 (71–87) |
| Blood pressure (mmHg) | ||||
| Systolic | 123 ± 14 | 130 ± 13* | 126 ± 14 | 148 ± 21* |
| Diastolic | 75 ± 8 | 80 ± 8 | 77 ± 8 | 90 ± 11* |
| Glucose (mmol/L) | 4.8 (4.5–5.1) | 5.0 (4.7–5.4)* | 4.9 (4.6–5.2) | 4.7 (4.4–5.1)† |
| Insulin (μU/mL) | 4.2 (2.9–5.5) | 5.7 (4.4–10.0)* | 4.8 (3.3–6.7) | 7.7 (6.1–10.7)* |
| HOMA-IR | 1.0 (0.8–1.5) | 1.3 (0.8–2.0)† | 1.1 (0.8–1.6) | 1.6 (1.1–2.2)* |
| Cholesterol (mmol/L) | 4.5 ± 0.9 | 4.9 ± 0.9* | 4.7 ± 0.9 | 5.3 ± 1.1* |
| Triglycerides (mmol/L) | 0.8 (0.7–1.1) | 1.1 (0.8–1.4) | 0.9 (0.7–1.2) | 1.2 (0.8–1.6)* |
| HDL cholesterol (mmol/L) | ||||
| Male | 1.5 ± 0.3 | 1.4 ± 0.3† | 1.4 ± 0.3 | 1.3 ± 0.3† |
| Female | 1.8 ± 0.3 | 1.6 ± 0.4† | 1.7 ± 0.4 | 1.8 ± 0.4 |
| LPS (EU/mL) | 60 (44–80) | 62 (49–82) | 61 (44–79) | 49 (40–55)* |
| LPS/HDL ratio | 37 (28–51) | 45 (35–62)* | 41 (30–54) | 34 (26–43)* |
| CRP (mg/L) | 0.7 (0.5–1.5) | 1.2 (0.7–3.3)† | 0.9 (0.5–2.0) | 1.7 (0.8–2.9)* |
| Medication (%) | ||||
| Lipid-lowering | 1 | 0 | 1 | 19* |
| Antihypertensive | 2 | 4 | 3 | 56* |
| Smoking (%) | 14 | 21 | 16 | 15 |
Continuous values are presented as median (interquartile range) or as mean ± SD.
NDC-lean (BMI ≤ 25 kg/m2) and NDC-ow (BMI >25 kg/m2) are compared with each other; NDC-all (NDC-lean + NDC-ow) and IgAGN groups are compared with each other.
*P ≤ 0.001,
†P ≤ 0.05.